Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and agonistic antibodies
against TRAIL death receptors (DR) kill tumor cells while causing virtually no damage to …

PARP inhibitors represent a major breakthrough in ovarian cancer care. Almost half of all
ovarian cancers have deficiencies in the homologous recombination (HR) DNA repair …

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors are attractive
therapeutic targets in cancer because agents that activate these receptors directly induce …

Background Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously
shown efficacy in a phase 2 study when given in capsule formulation to all-comer patients …

Background Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously
been shown to extend progression-free survival versus placebo when given to patients with …

Background We tested the hypothesis that ovarian cancers associated with germ-line
mutations of BRCA1 have distinct clinical and pathological features as compared with …

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the
United States, with less than half of patients living> 5 years following diagnosis. The NCCN …

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the
United States and is the country's fifth most common cause of cancer mortality in women. A …

This selection from the NCCN Guidelines for Ovarian Cancer focuses on the less common
ovarian histopathologies (LCOHs), because new algorithms were added for LCOHs and …

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the
United States, with less than half of patients living> 5 years from diagnosis. A major …